FDA approves fixed dose atazanavir/cobicistat
24 March 2015. Related: Antiretrovirals.
Antiretrovirals
FDA approves fixed dose raltegravir/3TC formulation: Merck holds back from marketing in US
24 March 2015. Related: Antiretrovirals.
Dolutegravir and Truimeq approved in England
29 January 2015. Related: Antiretrovirals.
London prescribing guidelines updated to include dolutegravir and Triumeq
29 January 2015. Related: Antiretrovirals.
Adequate cerebrospinal fluid exposure of efavirenz when dosed at 400 mg
29 January 2015. Related: Antiretrovirals.
Savings to the NHS predicted from switching to generic antiretrovirals
1 December 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Lower dose efavirenz effective in two studies
1 December 2014. Related: Conference reports, Antiretrovirals.
Should tenofovir dose be 200 – 250 mg when used with protease inhibitors?
1 December 2014. Related: Conference reports, Antiretrovirals.
3TC inferior to FTC in Dutch cohort but interchangeable in other studies
1 December 2014. Related: Conference reports, Antiretrovirals.
Suicide not associated with efavirenz use in the D:A:D cohort study
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Efavirenz decreases exposure to hormonal contraceptive implant
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Increased risk of ART-related hepatotoxicity in HIV positive pregnant women
1 December 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Darunavir pharmacokinetics in pregnancy and postpartum
1 December 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Efavirenz-associated gynaecomastia reported to the national HIV and TB healthcare workers hotline in South Africa
1 December 2014. Related: Conference reports, Antiretrovirals, Side effects.
Infants start ART too late but improvement over time in Southern Africa
1 December 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Pregnancy a risk factor for poor antiretroviral treatment outcomes in South African adolescents
1 December 2014. Related: Conference reports, Antiretrovirals, Women's health, Pregnancy.
Equivalent efficacy with lower dose darunavir
1 December 2014. Related: Antiretrovirals, PK and drug interactions.
Antiretroviral studies at ICAAC 2014: darunavir-based FDC with TAF, cobicistat, doravirine, Stribild and gel formulation PrEP
1 October 2014. Related: Conference reports, Antiretrovirals, HIV prevention and transmission.
Switch from efavirenz to rilpivirine quells CNS toxicity, improves sleep
1 October 2014. Related: Conference reports, Antiretrovirals.
HIV persists in lung macrophages of people on suppressive ART
1 October 2014. Related: Conference reports, Antiretrovirals, Cure-related research.
Risk of CVD or type-2 diabetes according to change in BMI after starting ART
1 October 2014. Related: Conference reports, Antiretrovirals, Side effects.
Single-pill dolutegravir/abacavir/3TC (Triumeq) approved in EU and US
1 October 2014. Related: Antiretrovirals.
Cobicistat and elvitegravir approved in the US as single pills
1 October 2014. Related: Antiretrovirals.
Positive opinion to approve of darunavir/cobicistat in Europe
1 October 2014. Related: Antiretrovirals.
Pill A, Pill B: simplified second-line treatment for low-income countries
1 August 2014. Related: Conference reports, Antiretrovirals, Treatment access.
Update on paediatric antiretrovirals
1 August 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Is d4T a viable option for children in low-income countries?
1 August 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Short-term safety of atazanavir/ritonavir-based second line treatment in Zambia
1 August 2014. Related: Conference reports, Antiretrovirals.
Uptake of ART is influenced by distance to the health facility in rural Zambia
1 August 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Dolutegravir-based single-tablet regimen set for EU approval
1 August 2014. Related: Antiretrovirals.
The antiretroviral pipeline 2014
19 July 2014. Related: Pipeline report, Antiretrovirals.
The paediatric antiretroviral pipeline
19 July 2014. Related: Pipeline report, Antiretrovirals, Paediatric care.
Preventive technologies: antiretroviral and vaccine development
19 July 2014. Related: Pipeline report, Antiretrovirals, HIV prevention and transmission, Vaccines and microbicides.
50% of UK seroconverters start ART within 1.4 years of infection: treating during primary infection should be a patient choice
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
PIVOT study: further analysis from five-year PI/r monotherapy strategy study
27 May 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetics of antiretrovirals in pregnancy
27 May 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Better virologic outcomes with efavirenz vs lopinavir/ritonavir in pregnant women and no difference in risk of preterm birth
27 May 2014. Related: Conference reports, Antiretrovirals, Pregnancy.
Once daily lopinavir/ritonavir not recommended for routine use in children and adolescents
27 May 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
Early antiretroviral treatment in infants
27 May 2014. Related: Conference reports, Antiretrovirals, Paediatric care.
ARV pipeline: doravirine, GSK-744 and BMS-068
24 March 2014. Related: Conference reports, Antiretrovirals.
Viral load rebound rate of 35% using ritonavir-boosted PI monotherapy: results of five-year PIVOT study
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Dual therapy less effective at high viral load: NEAT 001 study with raltegravir/darunavir/r
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Atazanavir, raltegravir and darunavir virologically equivalent in naive patients but significant differences for tolerability: results from ACTG 5257
24 March 2014. Related: Conference reports, Antiretrovirals, Treatment strategies.
Pharmacokinetic targets for efavirenz might be too high
24 March 2014. Related: Conference reports, Antiretrovirals, PK and drug interactions.
Women, HIV research and antiretrovirals
1 February 2014. Related: Conference reports, Antiretrovirals, Women's health, Cure-related research.
Outcomes in infants exposed to lopinavir/ritonavir in utero
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Paediatric care.
Two percent rate of efavirenz discontinuation in an ART programme in Malawi
1 February 2014. Related: Conference reports, Antiretrovirals, Pregnancy, Side effects.
Dolutegravir approved in Europe
1 February 2014. Related: Antiretrovirals, Treatment access.
Dolutegravir superior to darunavir/r at week 48 in open label treatment naïve study
1 December 2013. Related: Conference reports, Antiretrovirals.
GSK744: 24-week results with oral integrase inhibitor planned for once-monthly injections
1 December 2013. Related: Conference reports, Antiretrovirals.
Cenicriviroc: 48 week results compared to efavirenz
1 December 2013. Related: Conference reports, Antiretrovirals.
Approaches to once-daily raltegravir: new formulation likely to require food
1 December 2013. Related: Conference reports, Antiretrovirals.
DSMB stops boosted atazanavir monotherapy study due to virological failure
1 December 2013. Related: Conference reports, Antiretrovirals.
Recreational drug use is common in HIV positive gay men and is extensive in a significant minority
1 December 2013. Related: Conference reports, Antiretrovirals.
Elvitegravir approved in EU: data on food and drug interactions
1 December 2013. Related: Antiretrovirals.
ViiV file 572-trii fixed dose combination in the US: positive opinion to approve dolutegravir in the EU
1 December 2013. Related: Antiretrovirals.
Raltegravir safe and effective in pregnancy in small French study
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Side effects common but mostly mild in women taking higher dose protease inhibitors in pregnancy
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Good safety profile with long-acting integrase inhibitor GSK744
1 October 2013. Related: Conference reports, Antiretrovirals.
TAF comparable to TDF in once-daily pill for ART-naive: 48-week results
1 October 2013. Related: Conference reports, Antiretrovirals.
Dolutegravir superior to darunavir at 48 weeks in open-label ART-naive trial
1 October 2013. Related: Conference reports, Antiretrovirals.
High prices for antiretrovirals in middle-income countries outside Africa
1 October 2013. Related: Conference reports, Antiretrovirals, Treatment access.
Comparable efficacy and pregnancy outcomes with boosted atazanavir and lopinavir at standard doses
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
PrEP gives little extra benefit in attempted conception if male partner is on ART
1 October 2013. Related: Conference reports, Antiretrovirals, Pregnancy.
Cobicistat approved as pharmacokinetic (PK) booster for atazanavir and darunavir in EU prior to the US
1 October 2013. Related: Antiretrovirals.